# COMMAND Study **Entity class:** Publication or research result **Type:** Clinical study **Collection:** [[collections/Neurotech|Neurotech]] **Primary source:** [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] ## Definition COMMAND is Synchron's early-feasibility study of a permanently implanted endovascular BCI. ## Relationships [[wiki/COMMAND Study|COMMAND]] is related to [[wiki/Synchron|Synchron]], [[wiki/Stentrode|Stentrode]], and [[wiki/Elad Levy|Elad Levy]]. <!-- BEGIN HUMANIZED RELATIONSHIPS 2026-09-11 --> This entry's documented connections are expressed in its definition and related-work routes, with provenance retained in the source-linked material. <!-- END HUMANIZED RELATIONSHIPS 2026-09-11 --> ## Source route [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] · [[collections/Neurotech|Neurotech]] ## Related Work in the Corpus <!-- BEGIN HUMANIZED CORPUS ROUTES 2026-09-11 --> - In [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]], **Synchron: The Minimally Invasive Counter-Geometry** provides the narrative context for **COMMAND Study**: The COMMAND early feasibility study (NCT05035823), the first FDA-approved trial of a permanently implanted BCI, completed in November 2025 with results presented by co-principal investigator Dr. <!-- END HUMANIZED CORPUS ROUTES 2026-09-11 -->